Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2

Status

Completed 2Withdrawn 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 2

Conditions

Breast Neoplasms 264Carcinoma, Non-Small-Cell Lung 219Neoplasms 218Leukemia, Myeloid, Acute 193Multiple Myeloma 178Colorectal Neoplasms 175Melanoma 165Prostatic Neoplasms 163Lymphoma 145Leukemia 142Lymphoma, Non-Hodgkin 133Glioblastoma 131Pancreatic Neoplasms 127Neoplasm Metastasis 118Lung Neoplasms 118Leukemia, Lymphocytic, Chronic, B-Cell 118Ovarian Neoplasms 112Precursor Cell Lymphoblastic Leukemia-Lymphoma 106Recurrence 97Myelodysplastic Syndromes 93Hodgkin Disease 92Lymphoma, Large B-Cell, Diffuse 89Lymphoma, Follicular 89Lymphoma, Mantle-Cell 83Head and Neck Neoplasms 79Carcinoma, Renal Cell 79Brain Neoplasms 77Sarcoma 73Carcinoma, Hepatocellular 73Squamous Cell Carcinoma of Head and Neck 71

Interventions

ruxolitinib 2sonidegib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Completed × Thrombocytosis × Clear all
NCT01787552 2020-04-15

A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF

Novartis

Phase 1/2 Completed
50 enrolled 23 charts
Myeloid

Blood Coagulation Disorders, Blood Platelet Disorders, Bone Marrow Diseases, Hematologic Diseases, Hemorrhagic Disorders, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Thrombocytosis, Primary Myelofibrosis

NCT00509899 2018-03-12

Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis

Incyte Corporation

Phase 1/2 Completed
154 enrolled 26 charts
Myeloid

Polycythemia Vera, Thrombocytosis, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡